An interventional study of baroloop System in Hypertension, sponsored by neuroloop GmbH. Terminated at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-13.
Sponsored by neuroloop GmbH (part of B. Braun) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Hypertension with a site in Netherlands — 22 open to participants now, 32 under way, 7 of them phase 3. Hypertension · Netherlands.
Among the 152 studies in Hypertension with a site in Netherlands, this one is the 124th largest by enrollment of the 127 interventional ones that give a count, is one of 5 that started in 2021, is one of 44 with no phase, and was the 120th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →22 of the 152 studies in Hypertension with a site in Netherlands are open now. Recruiting first, the newest first:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
Zuyderland Medisch Centrum · Sites in Netherlands
Ages 18+
Medtronic Vascular · Sites in Netherlands, Australia, Belgium and 6 more countries
Ages 18+
Alnylam Pharmaceuticals · Sites in Netherlands, United States, Argentina and 32 more countries
Ages 18+
Boehringer Ingelheim · Sites in Netherlands, United States, Argentina and 48 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 50 · Phase 4 18
First in 1997; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 139 across the 127 interventional studies, 626 across the 25 observational. Of the 103 that completed or were terminated, 38 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 152 have an industry lead sponsor. The 10 most frequent:
This study is registered under neuroloop GmbH, one of the names counted as B. Braun. Under that name alone:
neuroloop GmbH is the lead sponsor of 2 studies on the registry; none are open to participants now.
B. Braun has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertension with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT06256991University Medical Center GroningenPotassium Correction for RAAS Optimization in Chronic Kidney Disease | 2026-12 |
| NCT07294794University of BirminghamPersonalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension | 2026-12-31 |
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2027-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 152 studies in Hypertension with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The baroloop Study is a non-randomized, prospective, single-arm, multi center First in Human (FIH) study with the primary objective being the assessment of the safety and feasibility of using the baroloop System in subjects with uncontrollable hypertension. The secondary objective is to document the effect of the baroloop device on the blood pressure and quality of life in subjects with hypertension. Up to 10 subjects will be enrolled in up to 3 sites in Europe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects implanted with the baroloop device
Device: baroloop System
vagal nerve stimulation
Composite Major Adverse Event (MAE) Rate
The MAE rate is calculated based on the number of participants that either died, were hospitalized for hypertensive crisis after the first titration visit, or experienced any device or procedure-related serious adverse events.
Time frame: at 6 months post-treatment
Feasibility - Device Placement and Vagal Nerve Stimulation
Feasibility was calculated based on the number of participants in whom the baroloop system was successfully placed around a vagal nerve and stimulation of the nerve was possible. Stimulation of the vagus nerve was attempted for the first time after either 14 or 21 days; depending on the healing progress of the participant after the surgery. Therefore, feasibility (ability to place the device and ability to stimulate the nerve after the surgery) was either confirmed after 14 days or 21 days, depending on the healing progress of the participant after the surgery.
Time frame: Day 14 or Day 21 post-implantation
Change in Blood Pressure
Change in blood pressure recorded during intraoperative stimulation
Time frame: at the time of implantation
Change in 24-hour ABPM
Mean change of 24-hour ambulatory systolic and diastolic blood pressure post-treatment versus baseline
Time frame: 1, 3, 6, 12, 18 and 24 months
Composite MAE Rate
he MAE consists of all causes of death, hospitalization for hypertensive crisis post-titration, and any device or procedure-related serious adverse events
Time frame: 1, 3, 12, 18 and 24 months
Change in Office Blood Pressure
Mean change in office systolic and diastolic blood pressure
Time frame: 1, 3, 6, 12, 18 and 24 months
Change in Antihypertensive Drugs/Dosages
Changes in antihypertensive drugs/dosages post-implantation as analyzed by Daily Defined Dosages (WHO Definition) and total medications
Time frame: 1, 3, 6, 12, 18 and 24 months
Quality of Life Evaluation - Short Form (36) Health Survey
Quality of Life as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: Baseline, 1, 3, 6, 12, 18 and 24 months
| Milestone | Investigational Device |
|---|---|
| Started | 4 |
| Completed | 0 |
| Not completed | 4 |
| Withdrew: Device failure in all 4 patients | 4 |
The MAE rate is calculated based on the number of participants that either died, were hospitalized for hypertensive crisis after the first titration visit, or experienced any device or procedure-related serious adverse events.
| Participants | Investigational Device |
|---|---|
| Composite Major Adverse Event (MAE) Rate | 4 |
Feasibility was calculated based on the number of participants in whom the baroloop system was successfully placed around a vagal nerve and stimulation of the nerve was possible. Stimulation of the vagus nerve was attempted for the first time after either 14 or 21 days; depending on the healing progress of the participant after the surgery. Therefore, feasibility (ability to place the device and ability to stimulate the nerve after the surgery) was either confirmed after 14 days or 21 days, depending on the healing progress of the participant after the surgery.
| Participants | Investigational Device |
|---|---|
| Feasibility - Device Placement and Vagal Nerve Stimulation | 4 |
Change in blood pressure recorded during intraoperative stimulation
Results for this outcome have not been posted.
Mean change of 24-hour ambulatory systolic and diastolic blood pressure post-treatment versus baseline
Results for this outcome have not been posted.
he MAE consists of all causes of death, hospitalization for hypertensive crisis post-titration, and any device or procedure-related serious adverse events
Results for this outcome have not been posted.
Mean change in office systolic and diastolic blood pressure
Results for this outcome have not been posted.
Changes in antihypertensive drugs/dosages post-implantation as analyzed by Daily Defined Dosages (WHO Definition) and total medications
Results for this outcome have not been posted.
Quality of Life as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Results for this outcome have not been posted.
Collected over Adverse event data was collected for each patient until he or she left the study. As all patients exited the study due to device failure, the period of time AEs were collected varies from 95 to up to 598 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Investigational Device | 0/4 (0%) | 4/4 (100%) | 3/4 (75%) |
| Event | Investigational Device |
|---|---|
| explantation surgery due to device failureSurgical and medical procedures | 4/4 |
| Event | Investigational Device |
|---|---|
| Heart palpitations after medication increaseCardiac disorders | 2/4 |
| Dizziness after charging the deviceGeneral disorders | 1/4 |
| Pressure on larynxGeneral disorders | 1/4 |
| Reddening around chest wound after implant procedureSurgical and medical procedures | 1/4 |
| Abscess left groinInfections and infestations | 1/4 |
| DizzinessGeneral disorders | 1/4 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/4 |
| Covid 19 infectionInfections and infestations | 1/4 |
| Bursitis in left shoulderMusculoskeletal and connective tissue disorders | 1/4 |
| Chest pain, sensation of sickness, dyspneaRespiratory, thoracic and mediastinal disorders | 1/4 |
| Age, Categorical(Participants) | Investigational Device |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 4 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Investigational Device |
|---|---|
| Female | 1 |
| Male | 3 |
| Race (NIH/OMB)(Participants) | Investigational Device |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Investigational Device |
|---|---|
| Netherlands | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2021 to primary completion in Oct 2023, 29 months.
Results were first posted in May 2025, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.